title: Breast cancer: what's HER-2/neu got to do with it?
authors.affiliation: Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: Corinne
authors.initials: C
authors.lastname: Lenahan
authors.forename: Christopher
authors.initials: C
authors.lastname: Dennis
authors.forename: Nina V
authors.initials: NV
authors.lastname: Isakovich
authors.forename: Susan E
authors.initials: SE
authors.lastname: Pories
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017698:Postmenopause; D011237:Predictive Value of Tests; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood* / Q000235:genetics; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases